Med BioGene

Med BioGene Inc. is a life science company based in Vancouver, Canada, specializing in the development and commercialization of genomic-based diagnostic and prognostic tests for cancer. The company's flagship product, GeneFx Lung, is a validated 15-gene expression signature designed to identify patients with early-stage non-small cell lung cancer (NSCLC) who are at a high risk of recurrence following surgical resection. By providing a more precise prognosis than traditional TNM staging, GeneFx Lung assists oncologists in identifying candidates who may benefit most from adjuvant chemotherapy. The technology was developed in collaboration with the University Health Network and has been licensed to Helomics (a subsidiary of Predictive Oncology) for commercialization. Med BioGene continues to manage its intellectual property portfolio while exploring further opportunities in the personalized medicine space.